Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ERBB3_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ERBB3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ERBB3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ERBB3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERBB3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERBB3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ERBB3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERBB3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719114 | Breast | IDC | extrinsic apoptotic signaling pathway | 42/1434 | 219/18723 | 2.56e-08 | 1.73e-06 | 42 |
GO:007099714 | Breast | IDC | neuron death | 57/1434 | 361/18723 | 1.31e-07 | 7.38e-06 | 57 |
GO:005140213 | Breast | IDC | neuron apoptotic process | 42/1434 | 246/18723 | 7.21e-07 | 3.35e-05 | 42 |
GO:190121414 | Breast | IDC | regulation of neuron death | 48/1434 | 319/18723 | 5.01e-06 | 1.69e-04 | 48 |
GO:004352313 | Breast | IDC | regulation of neuron apoptotic process | 35/1434 | 212/18723 | 1.26e-05 | 3.29e-04 | 35 |
GO:004206014 | Breast | IDC | wound healing | 55/1434 | 422/18723 | 7.27e-05 | 1.45e-03 | 55 |
GO:004352411 | Breast | IDC | negative regulation of neuron apoptotic process | 23/1434 | 145/18723 | 6.58e-04 | 8.11e-03 | 23 |
GO:004206311 | Breast | IDC | gliogenesis | 39/1434 | 301/18723 | 8.63e-04 | 1.00e-02 | 39 |
GO:00100011 | Breast | IDC | glial cell differentiation | 31/1434 | 225/18723 | 1.04e-03 | 1.15e-02 | 31 |
GO:190121513 | Breast | IDC | negative regulation of neuron death | 29/1434 | 208/18723 | 1.23e-03 | 1.32e-02 | 29 |
GO:00071625 | Breast | IDC | negative regulation of cell adhesion | 37/1434 | 303/18723 | 3.27e-03 | 2.75e-02 | 37 |
GO:007099724 | Breast | DCIS | neuron death | 57/1390 | 361/18723 | 4.56e-08 | 2.84e-06 | 57 |
GO:009719123 | Breast | DCIS | extrinsic apoptotic signaling pathway | 40/1390 | 219/18723 | 9.43e-08 | 5.28e-06 | 40 |
GO:005140222 | Breast | DCIS | neuron apoptotic process | 43/1390 | 246/18723 | 1.16e-07 | 6.13e-06 | 43 |
GO:190121421 | Breast | DCIS | regulation of neuron death | 48/1390 | 319/18723 | 2.13e-06 | 7.79e-05 | 48 |
GO:004352321 | Breast | DCIS | regulation of neuron apoptotic process | 36/1390 | 212/18723 | 2.45e-06 | 8.68e-05 | 36 |
GO:004206024 | Breast | DCIS | wound healing | 54/1390 | 422/18723 | 6.09e-05 | 1.22e-03 | 54 |
GO:004352421 | Breast | DCIS | negative regulation of neuron apoptotic process | 23/1390 | 145/18723 | 4.27e-04 | 5.72e-03 | 23 |
GO:00420632 | Breast | DCIS | gliogenesis | 39/1390 | 301/18723 | 4.76e-04 | 6.25e-03 | 39 |
GO:00100012 | Breast | DCIS | glial cell differentiation | 31/1390 | 225/18723 | 6.24e-04 | 7.87e-03 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERBB3 | SNV | Missense_Mutation | novel | c.655N>C | p.Phe219Leu | p.F219L | P21860 | protein_coding | deleterious(0.01) | possibly_damaging(0.64) | TCGA-CV-7099-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | novel | c.2473N>T | p.Leu825Phe | p.L825F | P21860 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | novel | c.1400N>T | p.Ser467Phe | p.S467F | P21860 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-D6-6516-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | novel | c.2287A>T | p.Ile763Phe | p.I763F | P21860 | protein_coding | deleterious(0.01) | benign(0.294) | TCGA-D6-A4Z9-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | novel | c.1822N>G | p.Asn608Asp | p.N608D | P21860 | protein_coding | tolerated(0.27) | benign(0.053) | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD |
ERBB3 | SNV | Missense_Mutation | novel | c.600N>T | p.Glu200Asp | p.E200D | P21860 | protein_coding | tolerated(1) | benign(0) | TCGA-HD-7753-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | erbitux | CR |
ERBB3 | SNV | Missense_Mutation | novel | c.3440N>T | p.Ser1147Phe | p.S1147F | P21860 | protein_coding | deleterious(0.02) | benign(0.062) | TCGA-HD-7832-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | rs200017094 | c.3118N>T | p.Arg1040Trp | p.R1040W | P21860 | protein_coding | deleterious(0) | benign(0) | TCGA-P3-A5Q5-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | | c.3206N>G | p.Ser1069Cys | p.S1069C | P21860 | protein_coding | tolerated(0.18) | benign(0.219) | TCGA-P3-A5Q5-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ERBB3 | SNV | Missense_Mutation | novel | c.937N>C | p.Asp313His | p.D313H | P21860 | protein_coding | deleterious(0) | benign(0.017) | TCGA-P3-A5QF-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cetuximab | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | antibody | 252827373 | ELGEMTUMAB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | TRASTUZUMAB | TRASTUZUMAB | 23680147 |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 178101724 | | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | lapatinib | LAPATINIB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | CHEMBL2109406 | PATRITUMAB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | DACOMITINIB | DACOMITINIB | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | CDX-3379 | | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 315661317 | | |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | LAPATINIB | LAPATINIB | 25953157,25398453 |
2065 | ERBB3 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | PERTUZUMAB | PERTUZUMAB | 23680147 |